About 1,300 new jobs will be created as a result of the expansion, with the goal of boosting innovation, improving operational effectiveness, and simplifying procedures throughout the company’s international activities. The goal of AstraZeneca, which is to use cutting-edge technologies to enhance healthcare outcomes globally, will be greatly aided by these new positions.
The GITC currently occupies 334,000 square feet in Ramanujan IT City for its offices. Over the course of the next six months, an additional 180,000 square feet will be added as part of the planned expansion. As a result, AstraZeneca’s Chennai location will become its largest global capability center, demonstrating the company’s strategic emphasis on India as a vital hub for operational and technological excellence.
Leveraging cutting-edge technologies, such as enterprise platforms, artificial intelligence (AI), machine learning (ML), data science, and supply chain analytics, will be the main focus of the extended GITC. Because they increase efficiency, streamline procedures, and spur technical innovation throughout AstraZeneca’s international operations, these technologies will play a critical role in determining the results of healthcare. The center’s development from a conventional IT support service provider to a vital component driving AstraZeneca’s digital transformation underscores its significance in the organization’s worldwide strategy.
The GITC in Chennai has been essential to AstraZeneca’s digital transformation from its founding. It has been crucial in advancing technology delivery and productivity, advancing the company’s goal of providing patients all around the world with life-changing medications. With its expanded capabilities, the center will be able to contribute even more to AstraZeneca’s global operations.
More than 4,000 workers, including those at the GITC, work for AstraZeneca in India. The company’s goal is to develop a workforce that is competent, diversified, and prepared for the future. The Chennai site will remain a center for research and development as well as technology, bolstering AstraZeneca’s cutting-edge portfolio in specialized illness areas like respiratory, cardiology, oncology, and rare diseases.
AstraZeneca’s 45th year in India is commemorated by the investment in the GITC, underscoring the company’s sustained dedication to the nation. This expansion demonstrates AstraZeneca’s commitment to leading science and innovation as well as the company’s success in India. The company’s goal is to change the future of the healthcare business, and this strategic investment is part of its plan to leverage cutting edge technology to improve patient outcomes.
The expansion’s significance was highlighted by Dr. Sanjeev Panchal, Managing Director and Country President of AstraZeneca Pharma India, who said, “Our expansion in Chennai signifies AstraZeneca’s unwavering commitment to pioneering science and innovation.” “This strategic investment reinforces our aspiration to transform the future of the healthcare industry and underscores our dedication to improving patient outcomes through cutting-edge technology,” he continued.
The strategic choice made by AstraZeneca to expand the GITC in Chennai is in line with the company’s global objective of promoting innovation and enhancing healthcare outcomes. AstraZeneca wants to improve its operational capabilities and solidify its position as a leader in the healthcare sector by utilizing cutting-edge technologies and generating new employment possibilities. This expansion not only signals a major turning point in AstraZeneca’s Indian operations, but it also paves the way for more development and innovation in the healthcare industry.
SOURCE:
ECONOMIC TIMES
